Hints and tips:
Related Special Reports
...After the latter was bought by Swiss pharmaceutical group Roche in 2009, he rose through the ranks, becoming Genentech’s chief executive in 2017 and Roche’s head of pharma two years later....
...Roche said it was also reviewing its manufacturing operations to improve efficiency. It recently sold a large site in California to contract manufacturer Lonza for $1.2bn....
...It is the second bolt-on acquisition by Roche’s new chief executive Thomas Schinecker in less than two months. Schinecker needs to soothe investor jitters over Roche’s pipeline....
...Roche, whose stock has fallen 27 per cent in the past 12 months, is a case in point....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Roche shares closed up almost 3 per cent on Monday, but remain down 15 per cent this year....
...Roche will pay $7.1bn upfront and a near-term milestone payment of $150mn. Pfizer will keep the commercialisation rights outside the US and Japan....
...Roche is conducting phase 1 clinical trials in humans on the candidate drug, which targets a bacterium known as carbapenem-resistant Acinetobacter baumannii, or CRAB....
...Shares in Roche increased 5.1 per cent to SFr265.95....
President Yoon Suk Yeol has pledged to target private use of company vehicles
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
...A former Roche manager who joined the German group last year, Anderson said he acknowledged the appeal of a “pure play structure” of pharma, crop science and over-the-counter consumer drugs....
Success of biosimilars in lowering prices will depend on decisions from powerful pharmacy benefit managers
...Ubben disclosed a 0.83 per cent stake in Bayer a year ago, becoming a leading force behind the ousting of then chief executive Werner Baumann, who was replaced by Bill Anderson, a former Roche manager....
...Anderson, a former executive at Swiss rival Roche, said he was seeking to “rebase expectations”....
...Chief executive Bill Anderson, who joined last year after heading the pharma unit of Swiss rival Roche, said the decision “was not taken lightly” and had “considered investor input.”...
...Earnings: Oil major Shell, beverage maker AG Barr and air carrier Icelandair will report, as will casino operator Rank Group and biopharma companies Novozymes, Roche and Sanofi....
...Speaking at the lender’s annual general meeting in Basel on Wednesday, Kelleher argued that holding additional capital would put Swiss banks at a disadvantage to US and Asian competitors....
...The deal allowed Credit Suisse to cut its holdings of such assets from $75bn to $20bn. Apollo rebranded the business as Atlas....
...The legal quagmire is one of multiple challenges facing Bayer chief executive Bill Anderson, who joined from Swiss drugmaker Roche last year and has vowed to restore the fortunes of one of Germany’s best-known...
Wealthy customers are pouring more money than ever into customisation, pushing carmakers to invest in supply chains and dedicated teams
German group’s move follows media reports in home country alleging human rights abuses by staff of local partner in China
...Bondholders who bought into a diverse group do not like the prospect of holding debt in a smaller company riddled with problems....
...Novartis trades on a forward price/earnings ratio of 13.6, higher than some European peers such as Roche and Sanofi....
British driver switches from team that has powered record-breaking career
International Edition